Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Namodenoson - Can Fite Biopharma

Next Previous
X
Search
Drug Profile

Namodenoson - Can Fite Biopharma

Alternative Names: CF-102; Cl-IB-MECA

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Can-Fite BioPharma; Rabin Medical Center; Temple University School of Medicine
  • Class Amides; Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Iodobenzenes; Obesity therapies; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Pancreatic cancer
  • Preclinical Obesity
  • No development reported Colorectal cancer; Hepatic fibrosis; Malignant melanoma; Prostate cancer; Reperfusion injury
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 11 Jul 2024 Can-Fite BioPharma submits an application to the US FDA for Orphan Drug Designation for Namodenoson in the treatment of Pancreatic cancer
  • 10 Jun 2024 Can-Fite Biopharma receives an approval from the Institutional Review Board (IRB) of Rabin Medical Center for phase II trial for Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater)
  • 31 May 2024 Phase-II clinical trials in Pancreatic cancer (Lates-stage disease, Metastatic disease, Second-line therapy or greater) (PO) (NCT06387342)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top